{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:42:13Z","timestamp":1790948533804,"version":"4.1.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Treatment of high-risk soft-tissue sarcoma (STS) of extremity or trunk wall involves neoadjuvant chemotherapy (NACT) followed by surgery. Histopathological response could estimate patient outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize morphological changes in surgical specimens of patients treated with NACT with or without radiotherapy (RT) to identify histopathological features that stratify risk of recurrence and ultimately estimate the benefit from neoadjuvant treatments.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a preplanned prospective secondary analysis of the ISG-STS 1001 clinical trial, a study with both a randomized clinical trial (conducted between 2011 and 2016) and a nonrandomized patient cohort (included between 2016 and 2020) at 32 centers across Italy, Spain, France, and Poland. Participants were patients with STS randomly assigned to receive either anthracycline plus ifosfamide or histotype-tailored (also termed histology tailored) NACT. Data analyses were performed from January to June 2023.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Participants received 3 cycles of anthracycline plus ifosfamide or histotype-tailored NACT with or without RT followed by surgery.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was disease-free survival (DFS). Histopathological features considered included the proportion of stainable tumor cells, tumor necrosis, hemorrhage, fibrohistiocytic reaction with hemosiderin, sclerosis or fibrosis, and sclerohyalinosis. The proportion of stainable tumor cells was classified according to the European Organization for Research and Treatment of Cancer\u2013Soft Tissue and Bone Sarcoma Group categories or as absent or present. The continuous variable of sclerohyalinosis, expressed as a percentage, was categorized based on the second tertile of its distribution (20%). Tumor necrosis, hemorrhage, fibrohistiocytic reaction with hemosiderin, sclerosis or fibrosis, which were also expressed as a percentage, were classified as absent or present.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 388 patients (201 in randomized cohort, 187 in nonrandomized cohort; median [IQR] age, 50 [41-60] years; 245 males [63.1%]) were evaluable for histopathological response. In the randomized cohort, after a median (IQR) follow-up of 86 (70-99) months, 115 of 201 patients (57.2%) developed a disease recurrence. The proportion of stainable tumor cells (&amp;gt;1%) was not associated with DFS (hazard ratio [HR], 1.47; 95% CI, 0.36-5.98;\n P<\/jats:italic>\n \u2009=\u2009.59). Necrosis (&amp;gt;1%) was associated with shorter DFS (HR, 3.11; 95% CI, 1.36-7.14;\n P<\/jats:italic>\n \u2009=\u2009.007), while sclerohyalinosis greater than 20% was associated with longer DFS (HR, 0.51; 95% CI, 0.28-0.94;\n P<\/jats:italic>\n \u2009=\u2009.03). Exclusion of patients who received preoperative RT did not alter these associations. In patients randomly assigned to anthracycline plus ifosfamide (n\u2009=\u200998), sclerohyalinosis greater than 20% remained associated with longer DFS (HR, 0.24; 95% CI, 0.09-0.67;\n P<\/jats:italic>\n \u2009=\u2009.007). These findings were confirmed when a broader cohort (n\u2009=\u2009187) was included.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of a randomized clinical trial, the proportion of stainable tumor cells, currently considered as the most relevant posttreatment change, did not stratify patient risk. The findings support consideration of the presence of sclerohyalinosis (&amp;gt;20%) to identify patients with the best outcome after NACT.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.40177","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:31:05Z","timestamp":1762446665000},"page":"e2540177","source":"Crossref","is-referenced-by-count":6,"title":["Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas"],"prefix":"10.1001","volume":"8","author":[{"given":"Sandro","family":"Pasquali","sequence":"first","affiliation":[{"name":"Molecular Pharmacology, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Collini","sequence":"additional","affiliation":[{"name":"Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleofe","family":"Romagosa","sequence":"additional","affiliation":[{"name":"Pathology Department, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Coindre","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Bergoni\u00e9, Bordeaux, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1218 ACTION, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pizzamiglio","sequence":"additional","affiliation":[{"name":"Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verderio","sequence":"additional","affiliation":[{"name":"Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Duroni","sequence":"additional","affiliation":[{"name":"Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Barisella","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda SocioSanitaria Territoriale (ASST) Fatebenefratelli Sacco, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"},{"name":"Miller School of Medicine, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Quagliuolo","sequence":"additional","affiliation":[{"name":"Surgery Department, IRCCS Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin Broto","sequence":"additional","affiliation":[{"name":"Oncology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Lopez","family":"Pousa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quint\u00ed, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grignani","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Citt\u00e0 della Salute e della Scienza Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Brunello","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard & Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Centrum Onkologii, Instytutim, Marii Sklodowskiej-Curie, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Fontana","sequence":"additional","affiliation":[{"name":"Clinical Trial Center and Department of Epidemiology, IRCCS Ospedale Policlinico San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Orthopedic Oncology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Palassini","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Lorenzo","family":"Renne","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Giovanni","family":"Casali","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[{"name":"Department of Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sbaraglia","sequence":"additional","affiliation":[{"name":"Surgical Pathology and Cytopathology Unit, Department of Medicine\u2013DIMED, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gambarotti","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bagu\u00e9","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Paolo","family":"Dei Tos","sequence":"additional","affiliation":[{"name":"Surgical Pathology and Cytopathology Unit, Department of Medicine\u2013DIMED, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[{"name":"Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"2","key":"zoi251106r1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","article-title":"Association of molecular subtypes with pathologic response, PFS, and OS in a phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer.","volume":"30","author":"Lerner","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi251106r2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer.","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"issue":"13","key":"zoi251106r3","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1158\/1078-0432.CCR-21-3100","article-title":"Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.","volume":"28","author":"Yam","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi251106r4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.","volume":"25","author":"D\u2019Alessio","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi251106r5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up?.","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi251106r6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6","article-title":"Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor.","volume":"56","author":"Picci","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"zoi251106r7","first-page":"14","article-title":"Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.","volume":"101","author":"Huvos","year":"1977","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"zoi251106r8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO;2-7","article-title":"Reproducibility of a histopathologic grading system for adult soft tissue sarcoma.","volume":"58","author":"Coindre","year":"1986","journal-title":"Cancer"},{"issue":"1","key":"zoi251106r9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijc.2910330108","article-title":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.","volume":"33","author":"Trojani","year":"1984","journal-title":"Int J Cancer"},{"issue":"10","key":"zoi251106r10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"zoi251106r11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi251106r12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a randomised clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the Italian French Group (FSG) and the the Polish Sarcoma Group (PSG).","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"zoi251106r13","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi251106r14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.23.00908","article-title":"Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).","volume":"42","author":"Gronchi","year":"2024","journal-title":"J Clin Oncol"},{"key":"zoi251106r15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105220","article-title":"Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.","volume":"106","author":"Pasquali","year":"2024","journal-title":"EBioMedicine"},{"issue":"20","key":"zoi251106r16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi251106r17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2015.09.021","article-title":"Evaluation of response after neoadjuvant treatment in soft tissue sarcomas: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting.","volume":"53","author":"Wardelmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"zoi251106r18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00223077","article-title":"Classification of histopathologic changes following chemotherapy in Ewing\u2019s sarcoma of bone.","volume":"23","author":"van der Woude","year":"1994","journal-title":"Skeletal Radiol"},{"key":"zoi251106r19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/17453674.1997.11744718","article-title":"Tumour necrosis and prognosis in Ewing\u2019s sarcoma.","volume":"273","author":"Akerman","year":"1997","journal-title":"Acta Orthop Scand Suppl"},{"issue":"12","key":"zoi251106r20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi251106r21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1302\/0301-620X.98B8.37346","article-title":"Ewing\u2019s sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.","volume":"98-B","author":"Albergo","year":"2016","journal-title":"Bone Joint J"},{"issue":"7","key":"zoi251106r22","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ejso.2021.02.009","article-title":"Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: a retrospective analysis of available scoring tools.","volume":"47","author":"Righi","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"zoi251106r23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1148\/radiol.2512081403","article-title":"High-grade soft-tissue sarcomas: tumor response assessment\u2013pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.","volume":"251","author":"Stacchiotti","year":"2009","journal-title":"Radiology"},{"issue":"23","key":"zoi251106r24","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1002\/cncr.27624","article-title":"Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.","volume":"118","author":"Stacchiotti","year":"2012","journal-title":"Cancer"},{"issue":"21","key":"zoi251106r25","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/cncr.34945","article-title":"Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall.","volume":"129","author":"Danieli","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"zoi251106r26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ejso.2021.02.024","article-title":"Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: results of a retrospective multicenter study.","volume":"47","author":"Bonvalot","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"zoi251106r27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.05.007","article-title":"Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: a systematic review and meta-analysis.","volume":"69","author":"Salah","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"zoi251106r28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/02656736.2015.1109146","article-title":"Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.","volume":"32","author":"Andreou","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"zoi251106r29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/bjc.2014.635","article-title":"Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma.","volume":"112","author":"Andreou","year":"2015","journal-title":"Br J Cancer"},{"issue":"23","key":"zoi251106r30","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1002\/cncr.28945","article-title":"Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.","volume":"120","author":"Mullen","year":"2014","journal-title":"Cancer"},{"issue":"455","key":"zoi251106r31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.blo.0000238864.69486.59","article-title":"Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma.","volume":"455","author":"Menendez","year":"2007","journal-title":"Clin Orthop Relat Res"},{"issue":"13","key":"zoi251106r32","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.2001.19.13.3203","article-title":"Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.","volume":"19","author":"Eilber","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi251106r33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jso.23775","article-title":"Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma.","volume":"111","author":"Vaynrub","year":"2015","journal-title":"J Surg Oncol"},{"issue":"5","key":"zoi251106r34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00432-019-02885-4","article-title":"Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma.","volume":"145","author":"Gannon","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"zoi251106r35","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23240","article-title":"Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.","volume":"63","author":"Chang","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"zoi251106r36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2011.37.7218","article-title":"Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.","volume":"30","author":"Gronchi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi251106r37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jamaoncol.2023.0042","article-title":"Pathologic complete response and clinical outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: the NRG\/RTOG 9514 and 0630 nonrandomized clinical trials.","volume":"9","author":"Wang","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi251106r38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijrobp.2017.02.087","article-title":"Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score.","volume":"98","author":"Schaefer","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"zoi251106r39","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-23-3960","article-title":"Clinical implications and molecular features of extracellular matrix networks in soft tissue sarcomas.","volume":"30","author":"Pankova","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"zoi251106r40","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2159-8290.CD-13-0118","article-title":"Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.","volume":"3","author":"Eisinger-Mathason","year":"2013","journal-title":"Cancer Discov"},{"issue":"6","key":"zoi251106r41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.","volume":"32","author":"Rawson","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi251106r42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"zoi251106r43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-024-01614-w","article-title":"Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas.","volume":"17","author":"Guegan","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"12","key":"zoi251106r44","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","article-title":"Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.","volume":"27","author":"Gronchi","year":"2016","journal-title":"Ann Oncol"},{"key":"zoi251106r45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.01.071","article-title":"High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.","volume":"93","author":"Pasquali","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841045\/pasquali_2025_oi_251106_1761850435.01103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:31:10Z","timestamp":1762446670000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841045"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.40177","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}